# ImageneBio, Inc.
ImageneBio is a clinical-stage biotechnology company developing therapeutics targeting immunological and inflammatory diseases. The company was previously known as Ikena Oncology, Inc. until rebranding to ImageneBio in July 2025. Based in San Diego, California, the company operates in the biological products sector with a focus on advancing drug candidates through clinical development.
As a clinical-stage entity, ImageneBio has not yet generated meaningful revenue from marketed products. The company's business model centers on the advancement of its therapeutic pipeline, with operations and expenses concentrated in research, development, and clinical trial activities. Geographic operations are primarily centered in the United States.
Specific information regarding employee headcount, detailed clinical programs, or partnership arrangements is not publicly disclosed in readily available sources. The company's market capitalization of approximately $0.1 billion reflects its early-stage status and the capital requirements typical of biotechnology firms in clinical development phases.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.02 | $-1.02 | +37.4% | |
| 2023 | $-1.63 | $-1.63 | +14.2% | |
| 2022 | $-1.90 | $-1.90 | — | |
| 2021 | — | — | — |